Q-omics provides the consensus-scored ANKRD52 profile across patient tissues and cancer cell-line models. ANKRD52 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANKRD52 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, ANKRD52 protein abundance shows 31,519 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, and HNSC as cancer lineages where ANKRD52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD52 survival associations across molecular data types. ANKRD52 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD52 RNA expression–survival associations across cancer types. High ANKRD52 expression shows unfavorable associations in MESO, LIHC, KICH, CESC and SKCM, but favorable associations in SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ANKRD52 RNA expression.
This table summarizes ANKRD52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD52 shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, LIHC, STAD and COAD. The HNSC box plot shows higher ANKRD52 RNA expression in tumor versus normal tissue (log2 FC = +0.864, t-test p < 0.001).
This table shows molecular features associated with ANKRD52 in patient tissues and cancer cell lines. In patient samples, ANKRD52 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD52 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
